Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 95

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 95
---
 Aadi’s board of directors consulted with
members of Aadi’s management team and its outside financial and legal advisors at various times and considered a number of

- 60 -

potentially supportive factors in its deliberations, including the following principal factors (not in any relative order of importance) that Aadi’s board of directors believes support such determinations and recommendation.

| • |     | information concerning Aadi’s current and future business, financial performance and condition, assets and 
 liabilities, operations, risks, management and competitive position;                                       |

| • |     | current financial market conditions and historical market prices, volatility and trading information with respect 
 to the common stock of Aadi;                                                                                      |

| • |     | Aadi’s consideration of possible strategic alternatives, including entering into a transaction with another 
 party or liquidating the assets of Aadi;                                                                    |

| • |     | the cessation of the PRECISION1 trial in light of the analysis by the Independent Data Monitoring Committee that       
 demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval; |

| • |     | the consideration to be received by Aadi in the Divestiture; |

| • |     | the terms of the Divestiture Agreement, including the conditions to closing the Divestiture set forth therein and                                                                                                                          
 the terms governing Aadi’s ability to solicit and evaluate competing acquisition proposals or other proposals for competing strategic transactions (including the ability of Aadi’s board of directors to withdraw its recommendation that 
 stockholders vote in favor of the Divestiture if Aadi’s board of directors receives a superior proposal, subject to certain additional provisions and exceptions);                                                                         |

| • |     | the extensive process undertaken by Aadi’s board of directors and Leerink Partners to identify and evaluate                                                                                                                                             
 strategic alternatives available to Aadi, during which Leerink Partners contacted a total of 31 potentially interested parties (and received additional unsolicited inbound interest from four other parties), of which 23 participated in introductory 
 calls, 16 signed nondisclosure agreements (of which 10 opted to participate in Management meetings) and received virtual data room access to conduct commercial and scientific due diligence on FYARRO;                                                 |

| • |     | the proposal for, and Aadi’s evaluation of, the License Agreement entered into contemporaneously with the 
 Divestiture Agreement, and the transactions contemplated thereby, including the PIPE Financing;           |

| • |     | the improvement in the base purchase price offered by Kaken from $